Epimmune宣告发布HBV疫苗专利

moonshadow

Epimmune (EPMN) Announces Issuance Of Patent For Epitope-Based Vaccines Targeting Hepatitis B Virus


SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- Epimmune Inc. today announced the issuance of U.S. Patent No. 6,689,363, directed to compositions and methods of using antigen fragments, or epitopes, to induce cellular, or T cell, immune responses for the prevention or treatment of hepatitis B virus (HBV) infection. The issued claims are directed to vaccine compositions made up of epitopes from multiple HBV proteins, identified using Epimmune's proprietary epitope identification technology, designed to provide broader population coverage than prior vaccines.

Dr. Emile Loria, President and Chief Executive Officer of Epimmune said, "This is an important patent for the Company coming shortly after our partner, Genencor International, Inc., announced its anticipated launch of Phase I human clinical trials with a therapeutic hepatitis B vaccine incorporating our epitope technology. As we continue our transition from a research based to a product and clinical development based company, it is an integral part of our strategy to gain additional intellectual property protection for both our own and our partnered programs and products."

moonshadow

参考译文：


    Epimmune (EPMN)宣告发布靶向B型肝炎的基于抗原决定基的疫苗专利
       
      圣地亚哥2月18日——Epimmune公司今天宣布了发布No. 6,689,363号美国专利，该专利技术用于使用抗原片断或者抗原决定基来诱导细胞的，或者说T细胞的免疫应答反应的各种合成物和治疗方法。这些合成物和方法产生的免疫应答反应是以针对B型肝炎病毒（HBV）的预防和治疗为目的的。发布的声明的主要内容是由多重HBV蛋白质的抗原决定基组成的疫苗合成物，而这些蛋白质是使用Epimmune所拥有的旨在相比以前的疫苗提供更广的人口覆盖率的抗原决定基识别技术所识别出来的。
       
      Epimmune的领袖及首席执行官Emile Loria博士说：“在我们的合作伙伴Genencor Internationa公司宣布他们预期开展使用合并了我们的抗原决定基技术的治疗性HBV疫苗的第一期临床试验后不久，对公司而言，这是一项重要的专利。随着我们从一个基于研究的公司到一个基于产品和临床发展的公司的转型的继续，获得对我们自己和我们合作伙伴的项目和产品的额外的知识产权所有权保护是我们整个战略的一个组成部分。”